Sudeep Pharma share price today

Sudeep Pharma Ltd's share price was ₹1,068.30 at the close on 30 October 2026. It has been rising for 20 weeks. That is 17.7% above its average price over the last 200 trading days. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 39 weeks in a row.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Sudeep Pharma Ltd is in stage 2. The phase helps read everything below.

Since its first close in our records, on 28 November 2025, it has traded between ₹530 and ₹1,344, and at that close it sat 66% of the way up from that low.

Over the last 11 months the share price moved +38% while the NIFTY 500 moved −8%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: revenue up on a year earlier for 5 quarters in a row (every quarter we can compare), profit up on a year earlier for 4 quarters in a row and highest quarterly profit in 9 quarters.

1. Revenue up on a year earlier for 5 quarters in a row (every quarter we can compare)

   In the September 2026 quarter revenue was ₹197 crore, +20.9% on a year earlier.

   Why: Revenue rose because the pharma food nutrition business sold much more, led by phosphates used in food and nutrition.

   Next results: check whether specialty sales grow again from a year earlier, using the new contracts and without the rice program restarting.

   From the earnings call on 29 Oct 2026.

2. Profit up on a year earlier for 4 quarters in a row

   In the September 2026 quarter profit was ₹52 crore, +10.6% on a year earlier.

   Why: Profit rose because the company earned more per sale from higher value phosphates and bisglycinates and from factory savings.

   Next results: check whether margins stay around current levels, since management sees no further improvement until the next set of contracts is signed.

   From the earnings call on 29 Oct 2026.

3. Highest quarterly profit in 9 quarters

   Profit of ₹52 crore in the September 2026 quarter is the highest of the last 9 quarters.

   Why: Profit reached its highest level because the company earned more per sale from higher value phosphates and bisglycinates and from factory savings.

   Next results: check whether profit holds at this high level while the company absorbs costs from the new plant running below full use and from battery work that has not started earning.

   From the earnings call on 29 Oct 2026.

For July to September 2026 (the quarter ended 30 September 2026), Sudeep Pharma reported revenue of ₹197 crore, up 20.9% from ₹163 crore a year earlier, and a profit of ₹52.0 crore, up 10.6% from ₹47.0 crore.

Sudeep Pharma results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Sudeep Pharma's management discussed these results on a call held on 29 October 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

Sudeep Pharma closed at ₹1,068.30 on 30 October 2026, up 38.0% from ₹774.15 a year earlier (28 November 2025). Its highest weekly close since November 2025 was ₹1,329.30 on 4 September 2026.

Sudeep Pharma share price: then and now

Weekly closing prices. Each change is the move from that price to the 30 Oct 2026 close. A day's intraday high or low can go beyond these weekly closes.

56 weekly closes from 28 November 2025 to 30 October 2026.

30 Oct 2026: Sudeep Pharma closed at ₹1,068.30, up 10.6% on the week and down 11.0% on the month. 29 Oct 2026: Sudeep Pharma held its results call for July to September 2026. Management guided: Specialty positive on a year earlier growth Q3-Q4 on secured contracts alone ex-rice; NSS FY28 growth at core pace near 30% operating profit barring shocks.

Earlier

• Results for July to September 2026: Revenue up 20.9% and profit up 10.6% on a year earlier.
• 23 Jul 2026: ex-date for a dividend of ₹1.50 a share.

Sudeep Pharma paid ₹1.50 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.14% at the ₹1,068.30 close on 30 October 2026. The last was a dividend of ₹1.50 a share, ex-date 23 July 2026.

Sudeep Pharma dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here.

No. Sudeep Pharma Ltd paid out 0% of its profit as dividends in each of its last 7 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate.

From the NSE corporate-actions record, read 5 November 2026.

On the call for July to September 2026, held on 29 October 2026, Sudeep Pharma's management guided: Specialty positive on a year earlier growth Q3-Q4 on secured contracts alone ex-rice; NSS FY28 growth at core pace near 30% operating profit barring shocks.

“Currently, we do not see anyone close to producing battery-grade iron phosphate at a commercial level, so we would have an 18- to 24-month head start over anyone else who starts working on this now.”Shanil Bhayani, on the call for July to September 2026

What management guided

• Greenfield commercial supplies H2 FY27 largely Q4; FY28 utilisation 15-20%, steady-state nearly 75% over 3-4 years near 3x asset turn.
• Magnesium bisglycinate top-three PFN contributor in 2-3 years north of ₹100 crore, reaching 10-20% of PFN from Q4 and Q1 onward.
• Battery Phase 1 25,000 tons commercial operations April 2027; Dahej plant approval 3-6 months with commercial revenue in H2 FY28.
• Firm binding offtake volumes for initial and expanded scale to be detailed customer-wise in Q4 or next call.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for July to September 2026, 29 October 2026.

When Sudeep Pharma reports October to December 2026, these are the 3 checks that show whether the story is still on course. First: Specialty return to on a year earlier growth next quarter on contracted approvals without rice restart - check against flagged rebound.

Sudeep Pharma is not on any of our India lists this week.

Sudeep Pharma Ltd earned ₹52.0 Cr of net profit in the Sep 2026 quarter, +10.6% on the same quarter a year earlier. That is the 4th quarter in a row of profit growth. Full-year FY26 profit was ₹174 Cr. Over 6 years profit has grown 46.0% a year on average. That is 26.4% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹47.0 Cr.

For the full year, FY26 profit was ₹174 Cr (+25.2% on the year before).

Why profit moved: revenue changed +20.9% on a year earlier and the margin moved +3.0 percentage points. Most of the change came from keeping more of each sale.

On average over the last four quarters, profit changed +29.9% and revenue +27.7%. Profit and revenue are moving at about the same pace.

Sudeep Pharma Ltd reported ₹197 Cr of revenue in the Sep 2026 quarter, +20.9% on the same quarter a year earlier. That is the 6th quarter in a row with growth on the year before. Over 6 years it has grown 31.7% a year on average. The last full year, FY26, came in at ₹642 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹709 Cr.

FY26 revenue was ₹642 Cr, +27.9% on the year before.

Recent pace: the last four quarters grew +27.7% on average, against 31.7% a year over the longer run, so this year is growing slower than its own long-run rate.

Sudeep Pharma Ltd's operating margin was 37.0% in the Sep 2026 quarter, 3.0 percentage points higher than the same quarter a year ago. Across 7 years it has been between 20.0% and 40.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +3.1 percentage points on the year while gross margin changed +2.1 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

Over the last 3 years, 41% of Sudeep Pharma Ltd's reported profit came in as cash from its operations, a gap worth watching. In FY26 it brought in ₹70.0 Cr of operating cash against ₹174 Cr of profit. After ₹260 Cr of spending on assets, free cash was −₹190 Cr: it spent more than its operations brought in.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 41% of profit came in as cash: the cash cycle got 279 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page.

What to look at next: less of the profit turns into cash than it should, and the cash cycle is 279 days longer. The next section looks at where the cash is stuck.

Sudeep Pharma Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 372 days in FY26, up from 93 days in FY21. It spent ₹373 Cr on assets over the last 3 years. Customers take 129 days to pay, and stock sits for 356 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹642 Cr, each day of that cycle ties up about ₹1.8 Cr, so roughly ₹654 Cr is tied up in the business at any time.

FY26: customers took 129 days to pay and stock sat for 356 days, about 11.7 months of sales sitting as stock, for a full cycle of 372 days, longer than FY21's 93.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 356 days. Customers pay about 129 days after that. Suppliers are paid at 113 days. Together that makes the 372-day cycle.

Spending on assets: ₹373 Cr over the last 3 years, against ₹35.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹185 Cr (FY26): assets paid for that are not earning yet.

In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit.

Sudeep Pharma Ltd's P/E is 64.1×, near the high end of its own history: higher than 80% of past readings. Its usual P/E (the middle reading) is 51.6×, over 11 months of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

Why the multiple is where it is: over the past year earnings per share moved +7.3% while the price moved +38.0%. The price did better than earnings, which pushed the multiple up within its own range.

In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple.

Sudeep Pharma Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 7 quarters of 1 measure, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: with too little history, we say so rather than guess a direction.

One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Sudeep Pharma Ltd earned a ROCE of 28% in FY26. Its return on capital used (ROIC) is 5.8 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 27.1% net margin and 0.55× asset turnover (sales divided by assets).

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

Why the return is what it is (FY26): a 27.1% net margin × 0.55× asset turnover × 1.33× leverage (assets divided by equity) ≈ 19.8% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed.

The key test, return on capital used minus the cost of capital: 17.8% − 12.0% = +5.8 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value.

The 17.8% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 20.9%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.

Sudeep Pharma Ltd has total debt of ₹189 Cr against shareholder equity of ₹973 Cr as of Sep 2026, so its debt is 0.19× its equity, which is very little. Year by year, that ratio went from 0.28 in FY25 to 0.17 in FY26. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

No group of Sudeep Pharma Ltd's owners changed its stake by a full percentage point over the last 4 quarters. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

For Sudeep Pharma Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

67.3 out of 100, rank 1 of 3 in Chemicals - Speciality, with 70% of the evidence available.

Sudeep Pharma Ltd scores 67.3 out of 100 against the 3 companies it is compared with in Chemicals - Speciality, ranking 1. There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone.

The three scored parts add up to the total exactly: 33.5 + 27.5 + 6.3 = 67.3 (no relative-strength reading this week; its 20 points are shared across the other three). This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Sudeep Pharma ranks 1 of 3 Chemicals - Speciality companies on the 4-Factor Sector Score, with 67.3 out of 100.

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Chemicals - Speciality, all 3 compared on one page.

Sudeep Pharma is the largest of 3 Chemicals - Speciality companies on Sector Alpha by market value (scores of 30 October 2026). It is the largest. Just below it: Jubilant Agri & Consumer Products and Chembond Chemicals.

Chemicals - Speciality companies close in size

1. Sudeep Pharma Ltd ₹12,066 crore
2. Jubilant Agri & Consumer Products Ltd ₹2,903 crore
3. Chembond Chemicals Ltd ₹549 crore

All 3 Chemicals - Speciality companies, largest first

Companies close in size in other industries

523. Zensar Technologies Ltd ₹12,196 crore · IT - Software
524. JSW Holdings Ltd ₹12,100 crore · Finance - Holding Company
525. Sudeep Pharma Ltd ₹12,066 crore
526. Karamtara Engineering Ltd ₹12,065 crore
527. Sobha Ltd ₹12,031 crore · Realty - National

Sector Alpha, written by code from the published numbers. Data as of 30 October 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.